Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...

Merck and Siemens are to develop smart manufacturing technology. Cedrik Neike, CEO Digital Industries at Siemens (pictured ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

Lack of a skilled talent pool, and slow logistics operations are among the major challenges that could discourage India’s ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

And then for GARDASIL, that again, one is the doubling of the volume. So where we were in 2019, there was some capacity constraints on our manufacturing supply. The team under the direction of Sanat ...